RxDoctor Payments DataLook up a doctor →

Mark Tratenberg, DO

Rheumatology · Morristown, NJNPI 1780812461

Payments from drug & device makers

$23,066in general payments, 2019–2025

Across 1,100 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
  • Johnson & Johnson$5K
  • AbbVie$3K
  • Amgen$2K
  • UCB, Inc.$1K
  • GSK$1K
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$5,33023%
  • Speaking & faculty fees$1,1005%
  • Travel & lodging$3552%
  • Food & beverage$15,82769%
  • Education$4542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,066 in reported general payments places this provider in the 80th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$882,043
Medicare patients
436
Services billed
96,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$196,436
Cosentyx Sensoready PenSecukinumab16$147,122
BenlystaBelimumab15$130,350
EnbrelEtanercept13$112,250
Enbrel SureclickEtanercept12$99,606
RasuvoMethotrexate/Pf12$12,415
Colchicine92$6,165
Hydroxychloroquine Sulfate133$4,643
MethotrexateMethotrexate Sodium123$4,107
Mycophenolate Mofetil25$1,682
Lidocaine14$1,145
Allopurinol87$1,137
Prednisone129$1,063
Celecoxib53$935
Methylprednisolone111$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$1,012$130,35015 claims
AmgenEnbrel$2,175$112,25013 claims
Medexus Pharma, Inc.Rasuvo$39$12,41512 claims
Scilex Pharmaceuticals Inc.Colchicine$16$6,16592 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →